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1,25-dihydroxyvitamin D3 (1,25[OH]2VD3) has an antiproliferative effect on keratinocyte growth, and its derivatives
are used for the treatment of psoriasis. It was reported previously that 1,25[OH]2VD3 induced cell cycle arrest not
only at the G0/G1 phase but also at the G2/M phase. However, the mechanism of 1,25[OH]2VD3-induced G2/M phase
arrest in keratinocytes has not been fully understood. The addition of 108 to 106 M 1,25[OH]2VD3 to cultured
normal human keratinocytes enhanced the expression of Myt1 mRNA preceding Wee1 mRNA; 106 M 1,25[OH]2VD3
unregulated Myt1 mRNA from 6 h to 24 h and Wee1 mRNA from 12 to 48 h. Interestingly, the levels of phosphorylated
Cdc2 were increased between 6 h and 48 h after 1,25[OH]2VD3 treatment, although the expression levels of Cdc2
mRNA and its protein production were reduced. 1,25[OH]2VD3 also decreased the expression of cyclin B1, which
forms a complex with Cdc2. These data indicated that the increase of Myt1 and Wee1 induced the phosphorylation
of Cdc2 leading to G2/M arrest. In conclusion, the induction of Cdc2 phosphorylation due to the increase of Wee1
and Myt1 as well as the reduction of Cdc2 and cyclin B1 are involved in 1,25[OH]2VD3-induced G2/M arrest of
keratinocytes.
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The compound 1,25-dihydroxyvitamin D3 (1,25[OH]2VD3),
which is the hormonal form of vitamin D3, regulates cell
growth in a variety of cells (Walters, 1992). The skin is one of
the target organs for 1,25[OH]2VD3, and the vitamin D receptor
(VDR) is present in the cells of both the epidermis and the
dermis (Stumpf et al, 1979, 1984; Pillai et al, 1988; Milde et al,
1991). The effects of 1,25[OH]2VD3 on keratinocytes have
been investigated extensively, and well characterized in vitro
and in vivo. In the in vitro studies, 1,25[OH]2VD3 demonstrated
a potent inhibitory effect on proliferation, and promoted the
differentiation of both murine and human keratinocytes
(Hosomi et al, 1983; Smith et al, 1986; Matsumoto et al,
1990; Kobayashi et al, 1993; Gniadecki, 1996; Kobayashi et al,
1998; Segaert et al, 2000). The critical effects on the epidermis
are also manifested in vivo (Holick et al, 1987; Dubertret et al,
1992; el-Azhary et al, 1993; Langner et al, 1993).
Several reports have demonstrated that 1,25[OH]2VD3
suppresses keratinocyte growth through cell cycle regula-
tion. The most distinguished effect of 1,25[OH]2VD3 on cell
cycle regulation is G1 block. G1 block is associated with
changes of various kinds of cell cycle regulatory molecules:
increased levels of p21 (Segaert et al, 1997; Zhuang and
Burnstein, 1998; Moffatt et al, 2001), p27 (Segaert et al,
1997; Wang et al, 1997), and transforming growth factor-
bGF-b (Segaert et al, 1997), decreased Cdk2 activity (Wang
et al, 1997; Zhuang and Burnstein, 1998), reduced levels of
cyclin E (Zhang et al, 1996), repressed E2F transactivation
(Zhuang and Burnstein, 1998), and retinoblastoma hypo-
phosphorylation (Kobayashi et al, 1993; Segaert et al, 1997).
Interestingly, 1,25[OH]2VD3 induces the accumulation of
cells not only in the G1 compartment but also in the G2/M
compartment. These features have been noted in HL60 cell
cultures (Godyn et al, 1994; Zhang et al, 1996; Harrison et al,
1999), in breast cancer cell lines (Eisman et al, 1989a, b),
and also in human keratinocytes (Kobayashi et al, 1993). In
contrast to the numerous studies on the mechanism of G1
block in 1,25[OH]2VD3-treated keratinocytes, the underly-
ing mechanism of G2 block induced by 1,25[OH]2VD3 in
keratinocytes has not been reported.
Orderly progression through the cell cycle is mediated
by the activation of a highly conserved family of protein
kinases, namely, cyclin-dependent kinases (Cdks) (Pines,
1995; Morgan, 1997). Activation of a particular Cdk requires
binding to a specific regulatory subunit, which is termed
a cyclin. A pivotal regulatory step for G2/M transition in
eucaryotes is the activation of the cell division cycle (Cdc)2/
cyclin B complex (initially called the maturation or mitosis
promoting factor, MPF) (Coleman and Dunphy, 1994;
Morgan, 1997). Cdc2/cyclin B is maintained in an inactive
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form during the S and G2 phases by inhibitory phos-
phorylation of the Cdc2 residues threonine 14 (Thr14)
and tyrosine 15 (Tyr15), which are positioned within the
adenosine triphosphate (ATP)-binding cleft (Gould and
Nurse, 1989; Krek and Nigg, 1991; Jin et al, 1996). The
inhibitory phosphorylation of Cdc2 is modulated by the
Wee1 family protein kinases, i.e., human Wee1 and Myt1.
The Wee1 gene product is a tyrosine-specific protein
kinase, which locates in nucleus and phosphorylates
Cdc2 exclusively at Tyr15 (McGowan and Russell, 1993,
1995). The Myt1 kinase, which is a homologue of the
product of the mik1 gene, is a dual-specificity protein kinase
that phosphorylates Cdc2 at both the Thr14 and Tyr15
residues (Booher et al, 1997; Fattaey and Booher, 1997;
Gould and Nurse, 1989; Krek and Nigg, 1991; Mueller et al,
1995). Myt1 kinase is a membrane-associated protein that
localizes to the endoplasmic reticulum and Golgi complex
(Liu et al, 1997); except for inhibitory phosphorylation of
Cdc2, Myt1 seems to influence normal shuttling of the
Cdc2/cyclin B complex into the nucleus (Liu et al, 1999).
Phosphorylation of Tyr15 and Thr14 suppresses catalytic
activity of Cdc2 by disrupting the orientation of the ATP
molecule to the ATP-binding cleft of Cdc2 (Atherton-Fessler
et al, 1993; De Bondt et al, 1993). Cdc25 family members,
which are dual-specificity phosphatases, have been identi-
fied as positive regulators of Cdc2. They counteract Wee1/
Myt1 activities (Russell and Nurse, 1986; Sebastian et al,
1993). Dephosphorylation of the Thr14 and Tyr15 residues
of Cdc2 by Cdc25B (in the cytoplasm) and Cdc25C (in the
nucleus) in the late G2 phase activates the cyclin B/Cdc2
complex directly, and the accumulated, active Cdc2/
cyclin B1 then triggers the initiation of mitosis (Dunphy
and Kumagai, 1991; Strausfeld et al, 1991; Coleman and
Dunphy, 1994; Karlsson et al, 1999). Therefore, the active
status of the Cdc2/cyclin B complex is controlled by several
G2/M-specific cell cycle regulatory kinases and phospha-
tases that reversibly phosphorylate Cdc2.
To elucidate the mechanism of G2 block induced in
human keratinocytes by 1,25[OH]2VD3, we investigated
the effects of 1,25[OH]2VD3 on the regulatory molecules of
G2/M transit. We demonstrated here that 1,25[OH]2VD3
increased Wee1 and Myt1, and the phosphorylated Cdc2.
This provides a potential mechanism for the accumulation
of VD3-treated keratinocytes in the G2/M compartment.
Results
cDNA microarray analysis of the effect of 1,25[OH]2VD3
on Wee1, cyclin B1, Cdc25B, and Cdc25C in human
keratinocytes We initially studied the expression of cell
cycle-related genes in 1,25[OH]2VD3-treated keratino-
cytes using the cDNA microarray technique. Six hours of
stimulation with 1,25[OH]2VD3 modified the expression
patterns of four genes that are thought to be important
regulators of G2/M transition (Fig 1). The expression of the
Wee1 mRNA, whose protein product phosphorylates Cdc2
at Tyr15 and suppresses Cdc2 activity, was induced after
1,25[OH]2VD3 treatment. In contrast, the expression levels
of cyclin B1, Cdc25B, and Cdc25C were suppressed to
various degrees by 1,25[OH]2VD3. These data suggest the
possibility that 1,25[OH]2VD3 induces G2/M cell cycle arrest
in keratinocytes by affecting Cdc2/cyclin B1.
Effect of 1,25[OH]2VD3 on Wee1 and Myt1 in human
keratinocytes The cDNA microarray analysis showed that
1,25[OH]2VD3 upregulated the expression of the Wee1
gene. To ascertain the effect of 1,25[OH]2VD3 on Wee1, we
examined the level of Wee1 mRNA, and Wee1 protein in
1,25[OH]2VD3-treated human keratinocytes. Wee1 mRNA
expression was upregulated gradually in a time-dependent
manner from 12 h up to 48 h by 106 M of 1,25[OH]2VD3
(Fig 2A). The optimum induction of Wee1 mRNA was 6-fold
at 48 h compared with the control (vehicle). Wee1 protein
began to increase at 12 h and reached the maximum, 3-fold
at 48 h (Fig 2B). This time course of Wee1 protein induc-
tion is consistent with that of Wee1 mRNA. Furthermore,
1,25[OH]2VD3 increased Wee1 mRNA expression in a
concentration-dependent manner, 1.6-fold at 108 M, 2.4-
fold increase at 107M, and 4.0-fold 106 M (Fig 2C). Wee1
protein was increased almost similarly by the addition of
1,25[OH]2VD3 at 10
8, 107, and 106 (Fig 2D). These data
demonstrate that 1,25[OH]2VD3 increases both Wee1
mRNA and Wee1 protein similarly in human keratinocytes.
Since Myt1 is a Wee1 family kinase that has been shown
to phosphorylate Cdc2 both at Tyr15 and Thr14 (Mueller
et al, 1995; Booher et al, 1997; Fattaey and Booher, 1997),
we examined the effect of 1,25[OH]2VD3 on Myt1 expres-
sion. 1,25[OH]2VD3 enhanced the expression of Myt1
mRNA (Fig 3A). But the time course of Myt1 mRNA
induction by 1,25[OH]2VD3 was distinguished from that of
Wee1 mRNA. Myt1 mRNA increased markedly from 6 to
12 h, and decreased at 24 h. Then, Myt1 mRNA expres-
sion returned to the baseline level at 36 h. Myt1 protein
increased and decreased in the same time course as Myt1
mRNA (Fig 3B). 1,25[OH]2VD3 at 10
8, 107, and
106 M increased Myt1 mRNA, 2.3-, 3-, and 1.5-fold, res-
pectively, compared with the control (vehicle) (Fig 3C). The
optimum induction of Myt1 protein was also observed
at 107 M of 1,25[OH]2VD3 (Fig 3D). Taken together,
1,25[OH]2VD3 induces Myt1 kinase preceding Wee1 kinase
in human keratinocytes. Myt1 is localized in the cytoplasm
and Wee1 is localized in the nucleus. This difference of
localization may affect the time lag of Myt1 and Wee1
induction by 1,25[OH]2VD3 in human keratinocytes.
Effect of 1,25[OH]2VD3 on Cdc2 and phosphorylation
of Cdc2 in human keratinocytes Next, we assessed the
Figure1
1,25-dihydroxyvitamin D3 (1,25[OH]2VD3) regulates the expression
of regulators of G2/M transit. Normal human keratinocytes were
cultured for 6 h in MCDB medium that contained 1,25[OH]2VD3 (10
6
M) or vehicle, and RNA samples from these cells were analyzed using
the cDNA microarray. Red, green, and yellow signify increased,
decreased, and unchanged gene expression, respectively, in response
to 1,25[OH]2VD3. A, Wee1; B, cyclin B1; C, Cdc25B; D, Cdc25C.
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effect of 1,25[OH]2VD3 on Cdc2 and phosphorylated Cdc2,
since Wee1 and Myt1 participate in the inhibitory phosphor-
ylation of Cdc2 (McGowan and Russell, 1993; McGowan
and Russell, 1995; Mueller et al, 1995; Booher et al, 1997;
Fattaey and Booher, 1997).
The addition of 106 M 1,25[OH]2VD3 suppressed the
expression of the Cdc2 mRNA in a time-dependent manner
(Fig 4A). Cdc2 mRNA began to decrease at 12 h, and was
barely detectable at 36 h. Western blotting demonstrated
that 106 M of 1,25[OH]2VD3 reduced Cdc2 protein at 12 h,
and was barely detectable at 36 and 48 h like Cdc2 mRNA
expression (Fig 4B).
Interestingly, phosphorylated Cdc2 was upregulated by
1,25[OH]2VD3, although the overall level of Cdc2 protein
expression was decreased (Fig 4B). The level of phos-
phorylated Cdc2 increased from 6 h and reached a plateau
at 24–48 h. Therefore, the relative ratio of phosphorylated
Cdc2/total Cdc2 increased in a time-dependent manner,
about 10-fold at 48 h. Cdc2 protein was markedly reduced
in a concentration-dependent manner by addition of
1,25[OH]2VD3 at 10
8, 107, and 106 M (Fig 4C). In
contrast, phosphorylated Cdc2 was increased almost
equally by 1,25[OH]2VD3 at 10
8, 107, and 106 M (Fig 4C).
Taken together, these data indicate that treatment with
1,25[OH]2VD3 suppresses Cdc2 production and inhibits its
activity in human keratinocytes. This seems likely to result in
G2/M growth arrest of 1,25[OH]2VD3-treated keratinocytes
eventually.
Effect of 1,25[OH]2VD3 on cyclin B1 in human keratino-
cytes The cyclin B1 subunit is essential for Cdc2 activity,
and the level of cyclin B1 affects the activity of Cdc2 and
progression from the G2 to the M phase. So, we examined
the effect of 1,25[OH]2VD3 on cyclin B1 mRNA and protein.
The addition of 106 M 1,25[OH]2VD3 induced the decrease
of both cyclin B1 mRNA and cyclin B1 protein in a time-
Figure 2
1,25-dihydroxyvitamin D3 (1,25[OH]2VD3) increases the expression of Wee1 mRNA and protein. (A) Keratinocytes were incubated for the
indicated time periods in MCDB medium that contained either 1,25[OH]2VD3 (10
6 M) or the vehicle, and total RNA samples were collected. RT-PCR
was performed using specific primers for human Wee1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Wee1 mRNA expression was
firstly estimated using GAPDH as the internal reference, and then the relative levels of Wee1 mRNA for each time point in 1,25[OH]2VD3-treated cells
was estimated by using that of vehicle-treated cells at a corresponding time point. Lastly, the relative Wee1 mRNA expression was normalized
against that at 0 h as 1 U, and plotted in the graph. (B) Keratinocytes were cultured and stimulated as described in (A), and protein was extracted at
the indicated time. Western blotting was performed, and the levels of Wee1 protein expression were estimated using actin as the internal reference
and normalized against the value of 0 h as 1 U. (C) Keratinocytes were cultured in different concentrations of 1,25[OH]2VD3 or vehicle for 24 h. Wee1
mRNA expression was estimated using GAPDH as the internal reference, and normalized against the relative value for the vehicle-treated sample (0 M)
as 1 U. (D) Keratinocytes were cultured and stimulated as described in (C), and protein was extracted after 24 h of stimulation. Western blotting was
performed and the levels of Wee1 protein expression were estimated using actin as the internal reference and normalized against the value for the
vehicle-treated sample (0 M) as 1 U.
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dependent manner (Figs 5A,B). In addition, cyclin B1 mRNA
and protein were reduced in a concentration-dependent
manner by addition of 1,25[OH]2VD3 at 10
8, 107, and
106 M(Figs 5C,D), although cyclin B1 mRNA decreased
more remarkably than cyclin B1 protein. This suppression
of cyclin B1 may also contribute to G2/M growth arrest of
1,25[OH]2VD3-treated keratinocytes.
Discussion
We used a cDNA microarray to conduct a systematic
analysis of 1,25[OH]2VD3-dependent cell cycle regulation,
and found that 1,25[OH]2VD3 strongly induced the Wee1
family in keratinocytes. Accompanying Wee1 and Myt1
induction, 1,25[OH]2VD3 induced inhibitory phosphorylation
of Cdc2. This paper reports that Wee1 and Myt1 are target
molecules of 1,25[OH]2VD3, and that Wee1 and Myt1 might
be key molecules in 1,25[OH]2VD3-induced G2/M arrest in
keratinocytes. 1,25[OH]2VD3 is reported to induce G2/M
arrest in other cells (Godyn et al, 1994; Harrison et al, 1999).
Wee1 and Myt1 might be involved in the 1,25[OH]2VD3-
induced G2/M arrest of these cells.
Wee1 inhibits mitosis (McGowan and Russell, 1995).
Despite extensive studies of the functions of the Wee1
family, there are few reports on their mechanisms. Interest-
ingly, we found a time lag between Myt1 (6–12 h post-
stimulation) and Wee1 (12–48 h post-stimulation) induction,
which resulted in continuous phosphorylation of Cdc2
(6–48 h post-stimulation). Wee1 phosphorylates Cdc2 in
the nucleus, whereas Myt1 phosphorylates Cdc2 in the
cytoplasm. The significance of this localization and the
mechanism producing the time lag between Myt1 and Wee1
induction is unclear. We speculate that Myt1 kinase
phosphorylates and inhibits Cdc2 activation and nuclear
translocation of the Cdc2/cyclin B complex during the
early period of 1,25[OH]2VD3 treatment. Moreover, Cdc2
phosphorylation is retained as high in the late period
of 1,25[OH]2VD3 treatment, whereas the level of Wee1
increases steadily. Therefore, 1,25[OH]2VD3 might keep
Cdc2 inactive with the sequential increase in the two
kinases: Myt1 and Wee1 (Fig 6).
1,25[OH]2VD3 is a physiologically active ligand for VDR.
VDR forms stable receptor complexes preferentially as
heterodimers with the retinoid X receptor (RXR). The VDR-
RXR dimer binds vitamin D response elements (VDRE),
which are located in the promoters of 1,25[OH]2VD3-
Figure 3
1,25-dihydroxyvitamin D3 (1,25[OH]2VD3) increases the expression of Myt1 mRNA and Myt1 protein. (A) RT-PCR was performed using specific
primers for human Myt1 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and the relative intensity of Myt1 mRNA expression was
estimated as described in Fig 2A. (B) Western blotting was performed as described in Fig 2B, and the levels of Myt1 protein expression were
estimated and normalized as described in Fig 2B. (C) Keratinocytes were cultured in different concentrations of 1,25[OH]2VD3 or vehicle for 12 h.
The Myt1 mRNA expression was estimated and normalized as described in Fig 2C. (D) Keratinocytes were cultured and stimulated as described in
(C), and proteins were extracted after 12 h of stimulation. Western blotting was performed, and the levels of Myt1 protein expression were estimated
and normalized as described in Fig 2D.
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regulated genes. The Wee1 promoter does not contain a
confirmed VDRE, so the VDR-VDRE pathway might not
regulate Wee1 directly. A recent study found one activator
protein 1 (AP-1)-binding motif in the Wee1 promoter region,
and c-Fos transactivates the Wee1 kinase gene direct-
ly (Kawasaki et al, 2001). In addition, prolonged c-Fos
expression elicits abnormally increased expression of the
Wee1 gene, which induces and maintains inactive phos-
phorylation of Cdc2 kinase. Another study reported that
1,25(OH)2VD3 stimulates AP-1 DNA-binding activity in
keratinocytes (Johansen et al, 2003), and we confirmed
that 1,25(OH)2VD3 increased c-Fos mRNA expression and
AP-1 transcription beginning 6 h after stimulation in a time-
dependent manner (unpublished data). The increased c-Fos
and activated AP-1 transcription seem to be dependent on
the binding of 1,25[OH]2VD3 to its surface membrane
receptor, annexin II (Johansen et al, 2003). Combined with
these data, this AP-1 activation induced by 1,25(OH)2VD3
might contribute to 1,25(OH)2VD3-dependent Wee1 expres-
sion and inactive phosphorylation of Cdc2 kinase, and this
signal pathway might be independent of VDR.
Previous reports have indicated that Cdc2 phosphoryla-
tion is not the only mechanism that regulates G2 arrest, but
that Cdc2 and cyclin B1 levels are also related to the G2/M
transition (Kao et al, 1997; McVean et al, 2002). We found
that 1,25[OH]2VD3 decreased Cdc2 and cyclin B1 expres-
sion in human keratinocytes. Combined with the fact that
1,25[OH]2VD3 increases inhibitory phosphorylation of Cdc2,
1,25[OH]2VD3 suppresses Cdc2 activation efficiently, since
almost all the Cdc2 is inhibited by phosphorylation by
1,25[OH]2VD3, as shown in Figs 4B,C. Cdc2 expression
appears to be regulated at the mRNA level, and to begin 12
h after treatment. We postulate that 1,25[OH]2VD3 sup-
presses Cdc2 transcription. The basal promoter region of
human Cdc2 contains the E2F, E-box, and Sp1 motifs. Of
these, the E2F motif is important for activating the Cdc2
promoter (Shimizu et al, 1995). In the pRb/E2F pathway,
pRb is phosphorylated (inactive) and hypophosphorylated
(active) during the cell cycle, and hypophosphorylated pRb
appears to repress gene transcription via its interaction
with E2F (Harbour and Dean, 2000). 1,25(OH)2VD3 induces
hypophosphorylation of pRb in keratinocytes within 6 h of
treatment (Kobayashi et al, 1993). Therefore, 1,25(OH)2VD3
might suppress Cdc2 transcription via pRb activation
and consequent E2F silencing in keratinocytes. In fact,
1,25(OH)2VD3 blocks the transcription of E2F-regulated
genes, such as cyclins A and E, via the G1 CDK-pRb-E2F
pathway in MCF-7 cells (Jensen et al, 2001). Treatment of
keratinocytes with TGF-b1 also results in the formation of
a DNA-binding complex between pRb and E2F, which
contributes to suppressing the E2F-regulated Cdc2 gene
and inhibiting cell cycle progression (Herzinger et al, 1995).
Cyclin B1 and Cdc25 are also E2F-target genes. This
suggests an interesting link in 1,25(OH)2VD3-treated kera-
tinocytes between the G1 CDk-pRb-E2F pathway and the
mitotic kinase Cdc2. Since the CDk inhibitor p21 is a
1,25(OH)2VD3-regulated gene and 1,25(OH)2VD3 increases
p21 expression in a VDRE-dependent manner (Liu et al,
1996), 1,25(OH)2VD3 probably decreases Cdc2 expres-
sion via a VDR-dependent pathway. c-Myc deregulation
by 1,25(OH)2VD3 in keratinocytes (Matsumoto et al, 1990)
Figure 4
1,25-dihydroxyvitamin D3 (1,25[OH]2VD3) downregulates the ex-
pression of Cdc2 mRNA and Cdc2 protein, and increases the level
of phospho-Cdc2 protein. (A) Total RNA samples were collected as
described in Fig 2A. Cdc2 mRNA was detected by ribonuclease
protection assay, and the relative levels of Cdc2 mRNA expression
were estimated as described in Fig 2A and plotted on the graph. (B)
Western blotting was performed as described Fig 2B. The levels of
Cdc2 and phospho-Cdc2 protein expression were, respectively,
estimated against actin, the relative level of phospho-Cdc2 at each
point was estimated using total Cdc2 expression as the reference, and
then normalized against the relative value at 0 h as 1 U. (C)
Keratinocytes were cultured and stimulated as described Fig 2C, and
protein was extracted after 24 h of stimulation. Western blotting was
performed, and Cdc2 and phospho-Cdc2 protein level at each point
was estimated using actin as an internal reference. The relative levels of
phospho-Cdc2 against total Cdc2 protein at each time point were
normalized against that relative value at 0 M as 1 U.
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could also contribute partially to the decreased Cdc2 and
cyclin B1 expression. c-Myc activates the transcription of
Cdc2 and cyclin B1 by occupying the E-box (North et al,
1999; Menssen and Hermeking, 2002). Activation of JNK
and p38 reduces cyclin B1 mRNA expression (Garner et al,
2002) and 1,25(OH)2VD3 increases the activities of JNK and
SAPK kinase in normal keratinocytes (our unpublished
data). The reductions in Cdc2 and cyclin B1 expression
might contribute to the G2 arrest of human keratinocytes via
two pathways: (1) a reduction in the amount of Cdc2/cyclin
B1 complex and (2) a decrease in cyclin B1-dependent
Cdc2 activation.
In this report, we presented data obtained from samples
treated with a dose of 1,25(OH)2VD3 (10
6 M), which is
slightly higher than the dose of vitamin D3 ointment that
is used to treat psoriasis (25  50 mg per g or about 107 M).
Note that 107 M 1,25(OH)2VD3 elicited a remarkable effect
in our work in concentration-dependent experiments. We
also studied the temporal effect of 107 M 1,25(OH)2VD3
and found that its influence was apparent, but moderate,
compared with that of 106 M (data not shown). We present
the data for 106 M 1,25(OH)2VD3 because Kobayashi et al,
(1993) reported that G2/M accumulation was obvious in
106 M 1,25(OH)2VD3-treated keratinocytes and was
induced weakly by 107 M 1,25(OH)2VD3. Therefore, these
changes might occur under physiological conditions and
might contribute to the improvement of psoriatic skin
treated with vitamin D3 analogue ointments.
The 1,25(OH)2VD3 signaling pathways, via either VDR or
non-genomic signaling via a possible 1,25(OH)2VD3 mem-
brane receptor, are poorly understood. Our results suggest
that 1,25[OH]2VD3 induces G2/M arrest in normal human
keratinocytes by increasing the levels of Wee1 and Myt1,
which results in the inhibitory phosphorylation of Cdc2
(Fig 6). Furthermore, the decreased levels of Cdc2 and
cyclin B1 contribute to G2/M arrest. This is the first report
of the interaction of 1,25[OH]2VD3, Wee1, and Myt1, and
this paper presents new molecular mechanisms for
1,25[OH]2VD3-induced biological function.
Materials and Methods
Cell culture Normal human keratinocytes were cultured with
MCDB153 medium supplemented with insulin (5 mg per mL),
Figure 5
1,25-dihydroxyvitamin D3 (1,25[OH]2VD3 VD3) downregulates the expression of cyclin B1 mRNA and protein. (A) Ribonuclease protection
assay was performed as described in Fig 4A. The relative levels of cyclin B1 mRNA expression were estimated and normalized as described in Fig
2A. (B) Western blotting was performed as described in Fig 2B, and the levels of cyclin B1 protein expression were estimated and normalized as
described in Fig 2B. (C) Keratinocytes were cultured and stimulated as described in Fig 2C. Cyclin B1 mRNA expression was estimated and
normalized as described in Fig 2C. (D) Keratinocytes were cultured and stimulated as described in Fig 2B, and protein was extracted after 24 h of
stimulation. Western blotting was performed, and the levels of cyclin B1 protein expression were estimated and normalized as described in Fig 2D.
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hydrocortisone (5  107 M), ethanolamine (0.1 mM), phos-
phoethanolamine (0.1 mM), bovine hypothalamic extract (50 mg
per mL), and Ca2þ (0.03 mM) as previously described (Yamasaki et
al, 2003a). Second or third passage cells were used in all of the
experiments. All the procedures that involved human subjects
received prior approval from the Ethical Committee of Ehime
University School of Medicine, and all subjects provided written
informed consent.
Reagents 1,25[OH]2VD3 was a generous gift from Teijin Pharma-
ceutical Co. Ltd (Tokyo, Japan). The rabbit anti-human-Wee1, goat
anti-human-Myt1, and goat anti-human-actin antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz,
California). Mouse anti-human-cyclin B1 was obtained from
PharMingen (San Diego, California). The rabbit anti-human-Cdc2
and rabbit anti-human-phospho-Cdc2 (Tyr15) antibodies were
obtained from Cell Signaling Technology (Beverly, Massachusetts).
1,25[OH2VD3 treatment of human keratinocytes Subconfluent
human keratinocyte cultures were incubated with various concen-
trations (108, 107, and 106 M) of 1,25[OH]2VD3, or vehicle
(ethanol) alone. After 24 h, the cells were harvested and total RNA
and protein were extracted. For the time-course experiment, we
stimulated cells with 106 M 1,25[OH]2VD3 and extracted total
RNA and protein at 0, 6, 12, 24, 36, and 48 h.
cDNA microarray analysis The cDNA array analysis was per-
formed with the Atlas cDNA expression array system, which
includes human cell cycle-related genes (Clontech Laboratories
Inc., Palo Alto, California), according to the manufacturer’s
instructions. Briefly, keratinocytes were treated with 106 M
1,25[OH]2VD3 or vehicle for 6 h, and total RNA was isolated with
the Atlas Pure System (Clontech). One microgram of total RNA was
labeled with the cDNA Synthesis Primer Mix and [a-32P]dATP.
Each radioactively labeled probe mix was then hybridized with
a separate array membrane. After a high-stringency wash, the
hybridization pattern was analyzed by autoradiography. The
relative mRNA expression levels of stimulated keratinocytes were
assessed by comparison with those of the control cells. Red
indicated a signal that was enhanced by 1,25[OH]2VD3, and green
indicated a signal that was suppressed by 1,25[OH]2VD3. Yellow
indicated unchanged expression of mRNA.
RT-PCR analysis Total RNA from cultured human keratinocytes
was prepared using Isogen (Nippon Gene, Toyama, Japan), and
treated with 50 U per mL of DNase I (Clontech) at 371C for 30 min
to remove any genomic DNA contamination. The following spe-
cific primers were used for the PCR: human Wee1, 50-GGA-
CAGTGTCGTCGTAGAAAG-30 and 50-GGCAGCATTTGGGATT-
GAGGT-30; human Myt1, 50-AAGCTGGGTGACTTCGGACT-30 and
50-ACAGAACGCAGCTCGGAAGA-30; and human GAPDH (glycer-
aldehyde 3-phosphate dehydrogenase), 50-GAAGGTGAAGGTCG-
GAGTC-30 and 50-GAAGATGGTGATGGGATTTC-30. The RT-PCR
was performed using RT-PCR High Plus (Toyobo Co., Ltd, Osaka,
Japan) according to the manufacturer’s instructions. Briefly, 1 mg of
total RNA was added to a 50 mL reaction mixture that contained
10 mL of 5  reaction buffer, 6 mL of 2.5 mM dNTPs, 5 mL of 25 mM
Mn(OAc)2, 19 mL of RNase-free H2O, 2 mL of 10 U per mL RNase
inhibitor, 2 mL of 2.5 U per mL of rTth DNA polymerase, and 2 mL of
10 pmol per mL of each primer. The cDNA was reverse transcribed
from total RNA for 30 min at 601C and heated to 941C for 2 min.
Amplification was performed using the DNA Thermal Cycler (Astec,
Fukuoka, Japan) for 23–25 cycles. A cycle profile consisted of
1 min at 941C for denaturation, and 1.5 min at 531C–601C for
annealing and primer extension. A 5 mL sample of the reaction
mixture was electrophoresed on a 2.0% agarose gel that contained
ethidium bromide. The PCR products were also sequenced to
confirm proper amplification. We performed at least three inde-
pendent studies and confirmed similar results. One represen-
tative experiment is shown in the figures. The intensity of each
band was quantified using the NIH Image software. The relative
levels of Wee1 and Myt1 mRNA expression were estimated using
GAPDH mRNA expression of each time point as the internal
reference, and normalized against the respective relative level of
the control (the point at 0 h was considered as a control for the time
course, whereas the point at 0 M of 1,25[OH]2VD3 was considered
as a control for the concentration-dependent experiments) as 1 U.
Ribonuclease protection assay (RPA) Single-stranded anti-
sense riboprobes were prepared by in vitro transcription of human
cDNA fragments using the RiboQuant In Vitro Transcription Kit
(Pharmingen) in the presence of [a-32P]UTP. The hCC-1 and hCYC-
1 probe sets (Pharmingen) were used as the templates for in vitro
transcription. Samples of total RNA (10 mg each) were hybridized
with the 32P-labeled riboprobe and digested with RNase using the
RiboQuant RPA Kit (Pharmingen) according to the manufacturer’s
Figure 6
Schema of 1,25-dihydroxyvitamin D3 (1,25[OH]2VD3)-
induced G2/M arrest of keratinocytes. This sum-
marizes the possible mechanisms of 1,25[OH]2VD3-
induced G2/M arrest of keratinocytes. 1,25[OH]2VD3
induces Wee1 and Myt1 in keratinocytes, and these
kinases phosphorylate Cdc2 and inactivate the Cdc2
protein in keratinocytes, resulting in G2/M arrest. The sup-
pressed Cdc2 and cyclinB expression by 1,25[OH]2VD3
may also contribute to G2/M blockade.
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instructions. The hybridization products were separated on a gel
and exposed to a film as previously described (Yamasaki et al,
2003b). We performed at least three independent studies and
confirmed similar results. One representative experiment is shown
in figures. Band density was analyzed using the NIH Image
program. GAPDH bands are doublet, which may be due to that the
end of GAPDH mRNA is highly susceptible to the RNase digestion
even though it is double stranded. So, the sum of the two bands’
intensity was considered as GAPDH mRNA expression. The
relative levels of Cdc2 and cyclin B1 mRNA were estimated using
GAPDH as the internal reference, and normalized against the
respective relative values of the control signal as 1 U. The relative
values of Cdc2 and cyclin B1 mRNA were plotted on graphs.
Western blot analysis The cells were harvested by scraping in
extraction buffer that contained 150 mM NaCl, 1% NP40, 0.5%
deoxycholate, 0.1% SDS, 50 mM Tris-HCl (pH 7.4), and protease
inhibitors. Equal amounts of protein were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to
polyvinylidene difluoride membranes. The analysis was performed
using the Vistra ECF kit (Amersham Biosciences K.K., Tokyo,
Japan) and FluoroImager (Molecular Dynamics Inc., Sunnyvale,
California) as previously described (Yamasaki et al, 2003b). We
performed at least three independent studies and confirmed
similar results. One representative experiment is shown in figures.
The intensity of each band was quantified with ImageQuant
(Molecular Dynamics Inc.), the relative protein expressions were
estimated using actin as the internal reference, and normalized to
the control as 1 U. The relative values of proteins are plotted on the
graphs.
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